A careful and transparent research studies conducted by a team of experts in their own domain gets this global Uterine Cancer Drug Market research report done efficiently. This report merges all-inclusive industry analysis with precise evaluations and forecasts which all together gives absolute research solutions and brings maximum industry clarity for strategic decision making. When globalization is at the high level, businesses opt to take advantage of the global market for marketing and selling their product. And that is where this global market report assists them in the journey of achieving success globally.
Get Exclusive Sample Report + All Related Graphs & Charts Here
Global uterine cancer drug market is growing at a substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to the increase in incidence of gynecological cancers along with the growth in importance of targeted drug therapies.
The key market players in the global uterine cancer drug market are Elekta AB, Ability Pharma, Apotex Inc, Merck & Co. Inc, Novo Nordisk A/S, Bristol-Myers Squibb Company, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, ALLERGAN, Pfizer Inc, AstraZeneca, Eli Lilly and Company, Novartis AG, Hetero, Alnylam Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Biogen, AbbVie Inc, Gilead Sciences, Inc among others.
Uterine cancer is a type of cancer that occurs in the layers of the cells that forms the lining of uterus called endometrium. Symptoms include vaginal bleeding after menopause, pelvic pain and bleeding between periods. Uterine cancer can be detected at an early stage because it frequently produces abnormal vaginal bleeding and can be treated by removing the uterus surgically.
According to the American Cancer Society’s for the year 2019, estimated that in the United States there are about 61,880 new cases of uterine cancer will be diagnosed and about 12,160 women will die from uterine cancer. Rising awareness for the diagnosis of cancer and the presence of the developed healthcare infrastructure are expected to propel the market in the United States
Segmentation: Global Uterine Cancer Drug Market
By Types
- Endometrial Adenocarcinoma
- Adenosquamous Carcinoma
- Papillary Serous Carcinoma
- Uterine Sarcoma
By Mechanism of Action
- Angiogenesis Inhibitor
- Mammalian Target of Rapamycin (mTOR) Inhibitor
- Monoclonal Antibody
- Others
By Drugs
- Bevacizumab
- Everolimus
- Temsirolimus
- Pembrolizumab
- Carboplatin
- Others
By Therapy
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormone Therapy
By Treatment
- Medication
- Surgery
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Direct
- Online Pharmacy
- Retailers
- Others
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Geography
- North America
- Europe
- Asia-Pacific
- South America
- Middle East and Africa
Competitive Analysis:
Global uterine cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of uterine cancer drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
